Interventional oncology evolves through collaboration

Article

The Society of Interventional Radiology launched an interventional oncology task force (IOTF) last year to develop the emerging field. The task force sought to integrate research, education, clinical standards, practice building, and public outreach and put a face on interventional oncology in the U.S. and abroad. It also sought a strategic partnership between IRs and oncology specialists including clinicians, radiation therapists, and surgeons.

The Society of Interventional Radiology launched an interventional oncology task force (IOTF) last year to develop the emerging field. The task force sought to integrate research, education, clinical standards, practice building, and public outreach and put a face on interventional oncology in the U.S. and abroad. It also sought a strategic partnership between IRs and oncology specialists including clinicians, radiation therapists, and surgeons.

The IOTF convened for the first time at the 2004 SIR meeting. Members met again for strategic planning in February 2005 and presented their preliminary recommendations at this year's SIR meeting in New Orleans.

Efforts at the international level led to the first International Symposium on Image-Guided Therapy for Cancer in London in early May, when the first World Congress on Interventional Oncology was launched. The congress will convene next year at Lake Como, Italy. The SIR, the Cardiovascular and Interventional Radiological Society of Europe, and the American Society of Clinical Oncology cosponsor these events.

Before the IOTF came into being, the SIR's Research and Education Foundation called the first multidisciplinary meeting focused on interventional oncology in 2002. The panel featured prominent investigators from the National Cancer Institute, the National Institute of Biomedical Imaging and Bioengineering, and the Angiogenesis Foundation, among others. The group published the first research agenda in January 2004 (J Vasc Interv Radiol 2004;15:7-12).

The plan set out a five-year process to establish research models for treatment optimization, global standards for clinical trials, and interdisciplinary collaboration and dissemination of data to fuel further research. The researchers spotted potential hurdles, including clashes with corporate interests. They also recognized the need for guidelines that would not hamper technical or clinical progress.

Recent Videos
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
Related Content
© 2025 MJH Life Sciences

All rights reserved.